Page 2 - Dr Reddys Laboratories Ltd News

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Stocks to Watch today, Sept 25: Polycab, Waaree Energies, Akzo, Tata Steel

Stocks to Watch today, September 25, 2025: From Polycab to Akzo Nobel, here is a list of stocks that will be in focus today

Dr Reddy's and Hetero to sell generic HIV prevention drug for $40 a year

The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated US price of around $28,000 a year for branded Yeztugo

Stocks to Watch today, Sept 23: Adani Power, KEC Int, JBM Auto, Vedanta

Stocks to Watch today, September 23, 2025: JBM Auto, Vedanta, JK Lakshmi, Dr Reddy's Labs and other stocks will be in focus

Dr Reddy's launches 'Tegoprazan' in India for acid peptic diseases

Tegoprazan, a next-generation acid blocker, offers faster relief and lasting control for GERD, NERD, and gastric ulcers, addressing India's rising acid peptic disease burden

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

Dr Reddy's shares fell on Monday after the USFDA issued a Form 483 with five observations at its Hyderabad plant inspection

Stocks to watch today, Sep 11: Bajaj Finserv, DRL, Mazagon, Jupiter Wagons

Stocks to watch on Thursday, September 11: Keystone Realtors, RVNL, Deepak Fertilisers, Torrent Pharma and Adani Ports are among top stocks to track today.

Tariffs, costs, and shifting strategies: Indian pharma's new playbook

Analysts say Indian pharma firms will increase focus on non-US exports and the domestic market as US tariff threats persist, with firms exploring offshore manufacturing options

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr Reddy's launches novel drug for chronic constipation management

Dr Reddy's Laboratories on Tuesday said it has launched a first-in-class generic medication for chronic constipation in the country. The drug firm has launched Linaclotide, a first-in-class guanylate cyclase-C (GC-C), under the brand name Colozo. Linaclotide is a USFDA-approved medication indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in paediatric patients aged 6 to 17 years. "The launch of Colozo marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat in India last year," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said in a statement. With Colozo, the company continues to strengthen its commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with the goal to serve 1.5 bn patients by 2030, he ...

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Mixed Q1 results for top drug firms amid price erosion, tariff threat

Fresh launches boosted growth for players like Lupin, Torrent

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social